[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR20200441A - Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b - Google Patents

Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b

Info

Publication number
CR20200441A
CR20200441A CR20200441A CR20200441A CR20200441A CR 20200441 A CR20200441 A CR 20200441A CR 20200441 A CR20200441 A CR 20200441A CR 20200441 A CR20200441 A CR 20200441A CR 20200441 A CR20200441 A CR 20200441A
Authority
CR
Costa Rica
Prior art keywords
diseases
imidazopyrimidines
triazolopyrimidines
inhibitors
activity
Prior art date
Application number
CR20200441A
Other languages
English (en)
Inventor
Chao Qi
Zhiyong Yu
Fenglei Zhang
Pei Gan
Le Zhao
Chunhong He
Ding-Quan Qian
Heeoon Han
Matthew S Mccammant
Wenqing Yao
xiaozhao Wang
Taisheng Huang
Liangxing Wu
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CR20200441A publication Critical patent/CR20200441A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<p>La presente solicitud se refiere a compuestos de la Fórmula (I): o estereoisómeros o sales farmacéuticamente aceptables de estos, que modulan la actividad de los receptores de adenosina, tales como los subtipos A2A y A2B, y son útiles para el tratamiento de enfermedades relacionadas con la actividad de los receptores de adenosina, que incluyen, por ejemplo, cáncer, enfermedades inflamatorias, enfermedades cardiovasculares y enfermedades neurodegenerativas.</p>
CR20200441A 2018-02-27 2019-02-26 Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b CR20200441A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862635926P 2018-02-27 2018-02-27
US201862718216P 2018-08-13 2018-08-13
US201862721312P 2018-08-22 2018-08-22
US201962793015P 2019-01-16 2019-01-16
PCT/US2019/019582 WO2019168847A1 (en) 2018-02-27 2019-02-26 Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors

Publications (1)

Publication Number Publication Date
CR20200441A true CR20200441A (es) 2021-03-15

Family

ID=65911247

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20200441A CR20200441A (es) 2018-02-27 2019-02-26 Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
CR20230030A CR20230030A (es) 2018-02-27 2019-02-26 Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b (divisional 2020-0441)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20230030A CR20230030A (es) 2018-02-27 2019-02-26 Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b (divisional 2020-0441)

Country Status (19)

Country Link
US (3) US20190292188A1 (es)
EP (1) EP3759112A1 (es)
JP (2) JP7474709B2 (es)
KR (1) KR20200139153A (es)
CN (2) CN117903140A (es)
AU (2) AU2019227607C1 (es)
BR (2) BR112020017421A2 (es)
CA (1) CA3092470A1 (es)
CL (2) CL2020002198A1 (es)
CO (1) CO2020011908A2 (es)
CR (2) CR20200441A (es)
EC (1) ECSP20060827A (es)
IL (2) IL303087B1 (es)
MA (1) MA52422A (es)
MX (2) MX2020008949A (es)
PE (1) PE20211001A1 (es)
PH (1) PH12020551332A1 (es)
TW (1) TW202400599A (es)
WO (1) WO2019168847A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109963854B (zh) * 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
PL3611174T3 (pl) * 2017-04-07 2022-08-08 Medshine Discovery Inc. Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a
JP2020527593A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． １，８−ナフチリジノン化合物およびその使用
CN111163780A (zh) 2017-07-18 2020-05-15 诺维逊生物股份有限公司 作为腺苷拮抗剂的杂环化合物
CR20200441A (es) 2018-02-27 2021-03-15 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
CA3105721A1 (en) * 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
TWI820209B (zh) * 2018-09-12 2023-11-01 大陸商迪哲（江蘇）醫藥股份有限公司 三唑并－嘧啶化合物及其用途
US20210395255A1 (en) * 2018-11-20 2021-12-23 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
MX2021006026A (es) * 2018-11-30 2021-07-06 Tuojie Biotech Shanghai Co Ltd Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
CR20210336A (es) 2018-12-20 2021-12-06 Incyte Corp Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina
WO2020150676A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
BR112021013936A2 (pt) 2019-01-18 2021-09-21 Nuvation Bio Inc. Compostos heterocíclicos como antagonistas de adenosina
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
JP2022545923A (ja) * 2019-08-26 2022-11-01 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としてのトリアゾロピリミジン
MX2022007575A (es) 2020-01-03 2022-09-23 Incyte Corp Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos.
CN115551595A (zh) * 2020-01-03 2022-12-30 因赛特公司 Cd73抑制剂和a2a/a2b腺苷受体抑制剂组合疗法
TW202135824A (zh) 2020-01-03 2021-10-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ及ｐｄ－１／ｐｄ－ｌ１抑制劑之組合療法
WO2021156439A1 (en) * 2020-02-06 2021-08-12 Astrazeneca Ab Triazole compounds as adenosine receptor antagonists
CN111362939B (zh) * 2020-04-26 2021-08-03 山东梅奥华卫科技有限公司 一种帕布昔利布母核结构化合物的制备方法
KR20230157940A (ko) 2020-12-29 2023-11-17 인사이트 코포레이션 A2a/a2b 저해제, pd-1/pd-l1 저해제 및 항-cd73 항체를포함하는 병용 요법
CA3236342A1 (en) 2021-11-19 2023-05-25 Crossignal Therapeutics, Inc. Adenosine receptor antagonists
WO2023246846A1 (zh) * 2022-06-23 2023-12-28 成都恒昊创新科技有限公司 一种非螯合性非还原性铁死亡抑制剂及其制备方法和用途
KR102621694B1 (ko) * 2022-09-15 2024-01-08 주식회사 스탠다임 아데노신 a2a 수용체 길항제 및 이의 용도

Family Cites Families (261)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
DE19629378A1 (de) 1996-07-20 1998-01-29 Boehringer Ingelheim Kg Neue Triazolopurine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU743910B2 (en) 1997-03-24 2002-02-07 Kyowa Hakko Kirin Co., Ltd. {1,2,4}triazolo{1,5-c}pyrimidine derivatives
AU5620299A (en) 1998-08-11 2000-03-06 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
KR20010087361A (ko) 1998-09-22 2001-09-15 히라타 다다시 [1,2,4]트리아졸로[1,5-ｃ]피리미딘 유도체
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
NZ514914A (en) 1999-05-07 2004-09-24 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
DK1210428T3 (en) 1999-08-23 2015-06-15 Dana Farber Cancer Inst Inc PD-1, a receptor for B7-4 AND USE THEREOF
ATE353365T1 (de) 1999-08-23 2007-02-15 Dana Farber Cancer Inst Inc Neue b7-4 moleküle und deren verwendungen
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US20020009444A1 (en) 2000-04-25 2002-01-24 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
TWI288137B (en) 2000-05-26 2007-10-11 Schering Corp Adenosine A2a receptor antagonists
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
RU2250898C2 (ru) 2000-08-11 2005-04-27 Эйсай Ко., Лтд. Производные 2-аминопиридина, фармацевтическая композиция на их основе и способ лечения
EP1961767B1 (en) 2001-01-17 2012-03-07 Biosceptre International Limited Diagnosis and treatment of cancers and other conditions
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
WO2002096363A2 (en) 2001-05-30 2002-12-05 Alteon, Inc. Method for treating fibrotic diseases or other indications
EP1414464A4 (en) 2001-05-30 2005-06-22 Alteon Inc METHOD OF TREATING GLAUCOMA
PL369530A1 (en) 2001-09-19 2005-05-02 Aventis Pharma S.A. Chemical compounds
AU2002334969A1 (en) 2001-10-09 2003-04-22 Sylvie Barchechath Use of stat-6 inhibitors as therapeutic agents
IL161156A0 (en) 2001-10-30 2004-08-31 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
PE20030739A1 (es) * 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
CA2473026C (en) 2002-01-22 2011-05-03 Warner-Lambert Company Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2003068776A1 (fr) 2002-02-15 2003-08-21 Kyowa Hakko Kogyo Co., Ltd. Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US20060058320A1 (en) 2002-09-24 2006-03-16 Kyowa Hakko Kogyo Co., Ltd. [1,2,4] Triazolo[1,5-c]pyrimidine derivatives
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
NZ542304A (en) 2003-03-14 2009-07-31 Ono Pharmaceutical Co Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
UA91961C2 (ru) 2003-04-09 2010-09-27 Дженентек, Инк. Лечение аутоимунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
WO2004092172A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
ATE418555T1 (de) 2003-04-09 2009-01-15 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
JP4778894B2 (ja) 2003-06-10 2011-09-21 協和発酵キリン株式会社 不安障害の治療方法
EP1639014B1 (en) 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
WO2005016892A1 (en) 2003-08-14 2005-02-24 F. Hoffmann-La Roche Ag Gabanergic modulators
CA2536408A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
GB0403819D0 (en) 2004-02-20 2004-03-24 Merck Sharp & Dohme New compounds
DK1737459T3 (da) 2004-03-19 2009-10-26 Warner Lambert Co Imidazopyridin og imidazopyrimidinderivater som antibakterielle midler
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2005118555A1 (en) 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1912643A2 (en) 2004-06-23 2008-04-23 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
MXPA06014637A (es) 2004-06-25 2007-02-12 Amgen Inc Triazoles e indazoles condensados utiles en el tratamiento de enfermedades mediadas por citocinas y otras enfermedades.
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
AU2005295579B2 (en) 2004-10-15 2011-08-04 NortonLifeLock Inc. One time password
US20060211739A1 (en) 2005-02-08 2006-09-21 Arturo Perez-Medrano Use of selective P2X7 receptor antagonists
CA3151350A1 (en) 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
AU2006247064A1 (en) 2005-05-18 2006-11-23 Biogen Idec Inc. Methods for treating fibrotic conditions
WO2006129626A1 (ja) 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法
ATE556712T1 (de) 2005-06-07 2012-05-15 Kyowa Hakko Kirin Co Ltd A2a antagonisten zur behandlung von motorischen störungen
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
JP4986451B2 (ja) 2005-06-30 2012-07-25 信一郎 礒部 マーキング剤
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
WO2007011759A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
CA2620223A1 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
AR056785A1 (es) 2005-11-10 2007-10-24 Schering Corp COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS
US7700594B2 (en) 2005-11-17 2010-04-20 Osi Pharmaceuticals, Inc. Fused bicyclic mTOR inhibitors
EP2233472B1 (en) 2006-03-28 2014-01-15 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
WO2007143434A2 (en) 2006-05-31 2007-12-13 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents
DE602007006010D1 (de) 2006-05-31 2010-06-02 Galapagos Nv Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
TWI423977B (zh) 2006-06-23 2014-01-21 Incyte Corp 作為ｈｍ７４ａ同效劑之嘌呤酮衍生物（一）
US8933130B2 (en) 2006-06-23 2015-01-13 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
JP5382692B2 (ja) 2006-07-10 2014-01-08 学校法人藤田学園 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
AU2007275221A1 (en) 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
DE102006041292A1 (de) 2006-09-01 2008-03-06 Henkel Kgaa Wasserstoffperoxid-Aktivierung mit N-Heterocyclen
WO2008037607A1 (de) 2006-09-25 2008-04-03 Basf Se Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen
WO2008056176A1 (en) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
JP2010511721A (ja) 2006-12-05 2010-04-15 ナショナル チャオ トン ユニバーシティ インダゾール化合物
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
MX2009010523A (es) 2007-04-10 2009-12-15 Lundbeck & Co As H Análogos de amidas heteroarílicas como antagonistas de p2x7.
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
WO2008138843A1 (en) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyridines and triazolopyrimidines useful for the treatment of joint degenerative & inflammatory diseases
PT2155747E (pt) 2007-05-10 2012-12-19 Ge Healthcare Ltd Imidazol(1,2-a)piridinas e compostos relacionados com actividade nos receptores de canabinóides cb2
HUP0700395A2 (en) 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
SI2170959T1 (sl) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
BRPI0813831A2 (pt) 2007-07-18 2015-01-06 Novartis Ag Compostos de heteroarila bicíclica e seu uso como inibidores de quinase
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
TW200922569A (en) 2007-08-10 2009-06-01 Genelabs Tech Inc Certain nitrogen containing bicyclic chemical entities for treating viral infections
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EA201000620A1 (ru) 2007-10-18 2010-12-30 Новартис Аг Ингибиторы csf-1r, предназначенные для лечения рака и заболеваний костей
US20090118301A1 (en) 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
EP2217069A4 (en) 2007-11-09 2012-03-14 Salk Inst For Biological Studi INHIBITORS OF NON-NUCLEOSIDE INHIBITORS OF THE REVERSE TRANSCRIPTASE
PE20091074A1 (es) 2007-12-13 2009-07-26 Bayer Healthcare Ag Triazolotriazinas y triazolopirazinas y su uso
PE20091268A1 (es) 2007-12-19 2009-09-19 Amgen Inc Derivados heterociclicos como inhibidores de pi3 quinasa
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CN102037157B (zh) 2008-03-21 2014-05-28 恩索恩公司 用多官能化合物促进金属对层压板的粘合力
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
JPWO2009128520A1 (ja) 2008-04-18 2011-08-04 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する複素環化合物
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
ES2658892T3 (es) 2008-07-23 2018-03-12 Kyowa Hakko Kirin Co., Ltd. Agente terapéutico para la migraña
US20120021519A1 (en) 2008-09-19 2012-01-26 Presidents And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
EP2345328A4 (en) 2008-09-19 2014-06-25 Sumitomo Chemical Co COMPOSITION FOR USE IN AGRICULTURE
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
DK4209510T5 (da) 2008-12-09 2024-07-22 Hoffmann La Roche Anti-pd-l1-antistoffer og deres anvendelse til at fremme t-cellefunktion
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
EP2210891A1 (en) 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
KR20100101054A (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
EP2509983B1 (en) 2009-11-16 2014-09-17 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
CA2793086C (en) 2010-03-18 2018-08-21 Institut Pasteur Korea Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
GB201007187D0 (en) 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination modulators
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
US20120083498A1 (en) 2010-06-17 2012-04-05 Fatah Kashanchi Modulators of Viral Transcription, and Methods and Compositions Therewith
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
MX2013002198A (es) 2010-08-27 2013-03-18 Merck Patent Gmbh Derivados de triazolopirazina.
EP3567042B1 (en) 2010-10-25 2021-07-07 G1 Therapeutics, Inc. Cdk inhibitors
ES2650744T3 (es) 2010-12-14 2018-01-22 Electrophoretics Limited Inhibidores de la caseína quinasa 1 delta (CK1delta)
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
JP5647374B2 (ja) 2011-03-23 2014-12-24 アムジエン・インコーポレーテツド Ｃｄｋ４／６およびｆｌｔ３の縮合三環系二重阻害剤
US9029389B2 (en) 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
EP2604265A1 (en) 2011-12-17 2013-06-19 Royal College of Surgeons in Ireland (RCSI) P2x7 antagonists as frontline or adjunctive treatment against status epilepticus
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
MX2014014468A (es) 2012-05-30 2015-02-12 Hoffmann La Roche Compuestos triazolo como inhibidores de fosfodiesterasa 10 (pde10).
EP2865671B1 (en) 2012-06-22 2017-11-01 Sumitomo Chemical Company, Ltd Fused heterocyclic compound
EP2882712A2 (en) 2012-07-27 2015-06-17 BIAL - Portela & Cª S.A. Process for the synthesis of substituted urea compounds
US9757379B2 (en) 2012-11-14 2017-09-12 The Board Of Regents Of The University Of Texas System Inhibition of HIF-2α heterodimerization with HIF1β (ARNT)
WO2014126580A1 (en) 2013-02-15 2014-08-21 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
WO2014152013A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
CA2918910A1 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
JP7032929B2 (ja) 2014-07-11 2022-03-09 ヴェンタナ メディカル システムズ， インク． 抗ｐｄ－ｌ１抗体及びその診断上の使用
MX2017004471A (es) 2014-10-06 2017-11-20 Flatley Discovery Lab Llc Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
JP7037359B2 (ja) 2014-10-10 2022-03-16 イナート・ファルマ・ソシエテ・アノニム Ｃｄ７３遮断
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
SG11201703332SA (en) 2014-11-10 2017-05-30 Medimmune Ltd Binding molecules specific for cd73 and uses thereof
EP3218407A1 (en) 2014-11-11 2017-09-20 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
ES2807182T3 (es) 2014-11-21 2021-02-22 Bristol Myers Squibb Co Anticuerpos frente a CD73 y sus usos
PT3257853T (pt) 2015-02-12 2021-12-23 Nissan Chemical Corp Composto heterocíclico condensado e agente de controlo de organismos prejudiciais
JP6697809B2 (ja) 2015-03-06 2020-05-27 ファーマケア，インク． フッ素化リシルオキシダーゼ様２阻害剤とその使用
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
CR20220194A (es) 2015-07-30 2022-06-16 Macrogenics Inc Moléculas de unión a pd-1 y métodos de uso de las mismas
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
PT3377488T (pt) 2015-11-19 2022-11-21 Incyte Corp Compostos heterocíclicos como imunomoduladores
US10822426B2 (en) 2015-12-09 2020-11-03 Corvus Pharmaceuticals, Inc. Humanized anti-CD73 antibodies
US20170174671A1 (en) 2015-12-17 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
MX2018007774A (es) 2015-12-22 2018-11-09 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
US10912776B2 (en) 2015-12-24 2021-02-09 Corvus Pharmaceuticals, Inc. Methods of treating cancer
EA035036B1 (ru) 2016-02-24 2020-04-20 Пфайзер Инк. Производные пиразоло[1,5-а]пиразин-4-ила в качестве ингибиторов янус-киназы (jak)
US10781218B2 (en) 2016-03-16 2020-09-22 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
PT3472167T (pt) 2016-06-20 2022-11-11 Incyte Corp Compostos heterocíclicos como imunomoduladores
WO2017223414A1 (en) * 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
WO2018004478A1 (en) 2016-06-29 2018-01-04 Hayat Kimya San. A. Ş. An improved method of soft nonwoven fabric production
US10793636B2 (en) 2016-07-11 2020-10-06 Corvus Pharmaceuticals, Inc. Anti-CD73 antibodies
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US10472363B2 (en) 2016-09-02 2019-11-12 Cyclerion Therapeutics, Inc. SGC stimulators
CA3046432A1 (en) 2016-12-13 2018-06-21 Astellas Pharma Inc. Anti-human cd73 antibody
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
PE20200005A1 (es) 2016-12-22 2020-01-06 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
JP7303108B2 (ja) 2016-12-22 2023-07-04 インサイト・コーポレイション 免疫調節剤としての二環式複素芳香環化合物
GEP20227428B (en) 2016-12-22 2022-10-25 Incyte Corp Heterocyclic compounds as immunomodulators
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
TWI820013B (zh) 2017-01-23 2023-11-01 美商銳新醫藥公司 作為別構ｓｈｐ２抑制劑之雙環化合物
HUE058975T2 (hu) 2017-01-24 2022-09-28 I Mab Biopharma Us Ltd CD73-ellenes antitestek és alkalmazásaik
CN109963854B (zh) 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
US20210107989A1 (en) 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
PL3611174T3 (pl) * 2017-04-07 2022-08-08 Medshine Discovery Inc. Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a
EP3630830A1 (en) 2017-05-23 2020-04-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
MA49457A (fr) 2017-06-22 2020-04-29 Novartis Ag Molécules d'anticorps se liant à cd73 et leurs utilisations
US20200369665A1 (en) 2017-06-30 2020-11-26 Ryvu Therapeutics S.A. Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor
CN109535161B (zh) * 2017-09-22 2021-09-03 江苏恒瑞医药股份有限公司 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
KR20200076686A (ko) 2017-10-24 2020-06-29 바이엘 악티엔게젤샤프트 치환된 이미다조피리딘 아미드 및 그의 용도
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP2021512109A (ja) 2018-01-31 2021-05-13 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
EP3752251A1 (en) 2018-02-17 2020-12-23 AstraZeneca AB Arginase inhibitors and methods of use thereof
CR20200441A (es) 2018-02-27 2021-03-15 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
WO2019170131A1 (zh) 2018-03-07 2019-09-12 复旦大学 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
CA3093468A1 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
AU2019231172B2 (en) 2018-03-09 2023-08-24 Phanes Therapeutics, Inc. Anti-CD73 antibodies and uses thereof
CA3095758A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Heterocyclic compounds as immunomodulators
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
US20210147570A1 (en) 2018-04-12 2021-05-20 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
JP7328995B2 (ja) 2018-05-11 2023-08-17 インサイト・コーポレイション Ｐｄ－ｌ１免疫調節剤としてのテトラヒドロ－イミダゾ［４，５－ｃ］ピリジン誘導体
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
US20200095322A1 (en) 2018-06-20 2020-03-26 Incyte Corporation Anti-pd-1 antibodies and uses thereof
CA3105721A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
MX2020013719A (es) 2018-08-13 2021-03-02 Hoffmann La Roche Nuevos compuestos heterociclicos como inhibidores de monoacilglicerol lipasa.
JP2021534139A (ja) 2018-08-13 2021-12-09 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft モノアシルグリセロールリパーゼ阻害剤としての新規の複素環化合物
KR102668252B1 (ko) 2018-08-22 2024-05-21 아스트라제네카 아베 아르기나제 저해제 및 이의 사용 방법
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
TWI820209B (zh) * 2018-09-12 2023-11-01 大陸商迪哲（江蘇）醫藥股份有限公司 三唑并－嘧啶化合物及其用途
WO2020069027A1 (en) 2018-09-26 2020-04-02 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
CN111295384B (zh) 2018-10-10 2022-08-12 江苏豪森药业集团有限公司 双环类衍生物抑制剂、其制备方法和应用
AR117188A1 (es) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
BR112021010358A2 (pt) 2018-11-30 2021-08-24 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Derivados heteroaromáticos para uso como regulador, método para preparar os mesmos e uso dos mesmos
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
JP2022545923A (ja) 2019-08-26 2022-11-01 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としてのトリアゾロピリミジン
CA3155852A1 (en) 2019-09-30 2021-04-08 Incyte Corporation PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS
EP4058461A1 (en) 2019-11-11 2022-09-21 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
MX2022007575A (es) 2020-01-03 2022-09-23 Incyte Corp Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos.
TW202135824A (zh) 2020-01-03 2021-10-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ及ｐｄ－１／ｐｄ－ｌ１抑制劑之組合療法
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
KR20230157940A (ko) 2020-12-29 2023-11-17 인사이트 코포레이션 A2a/a2b 저해제, pd-1/pd-l1 저해제 및 항-cd73 항체를포함하는 병용 요법

Also Published As

Publication number Publication date
CN112384515A (zh) 2021-02-19
CL2020002198A1 (es) 2021-01-29
MX2020008949A (es) 2021-01-08
IL303087A (en) 2023-07-01
JP7474709B2 (ja) 2024-04-25
PE20211001A1 (es) 2021-06-01
BR112020017421A2 (pt) 2020-12-22
KR20200139153A (ko) 2020-12-11
PH12020551332A1 (en) 2021-09-06
IL276873A (en) 2020-10-29
US20230357255A1 (en) 2023-11-09
AU2019227607B2 (en) 2023-04-27
CO2020011908A2 (es) 2020-10-30
WO2019168847A1 (en) 2019-09-06
JP2023123569A (ja) 2023-09-05
CL2022003185A1 (es) 2023-05-19
TW202400599A (zh) 2024-01-01
MA52422A (fr) 2021-01-06
ECSP20060827A (es) 2020-12-31
JP2021515036A (ja) 2021-06-17
CA3092470A1 (en) 2019-09-06
AU2022283611A1 (en) 2023-02-02
IL303087B1 (en) 2024-08-01
TW202000666A (zh) 2020-01-01
CR20230030A (es) 2023-03-10
MX2022014648A (es) 2022-12-15
US20210139485A1 (en) 2021-05-13
US20190292188A1 (en) 2019-09-26
AU2019227607C1 (en) 2023-07-20
US11673894B2 (en) 2023-06-13
EP3759112A1 (en) 2021-01-06
CN117903140A (zh) 2024-04-19
BR122023024273A2 (pt) 2024-02-20
AU2019227607A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
MX2022014648A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b.
MX2023008994A (es) Derivados de pirazina fusionados como inhibidores de a2a/a2b.
MX2020012376A (es) Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
MX2022002219A (es) Triazolopirimidinas como inhibidores de a2a/a2b.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX2021009117A (es) Pirazolopiridinas y triazolopiridinas como inhibidores receptores de adenosina a2a / a2b.
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MY202022A (en) Pyrrolotriazine compounds as tam inhibitors
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EA202092016A1 (ru) Имидазопиримидины и триазолопиримидины в качестве ингибиторов a2a/a2b
EA202190204A1 (ru) Производные конденсированных пиразинов как ингибиторы a2a/a2b
MY192305A (en) Bipyrazole derivatives as jak inhibitors